By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



29 Newbury Street

Boston  Massachusetts  02116  U.S.A.
Phone: 617-236-0535 Fax: 617-249-0490


Start Up

Company News
Zafgen (ZFGN) Announces Third Quarter 2015 Financial Results 11/11/2015 8:27:52 AM
Embattled Zafgen (ZFGN) Continues Obesity Clinical Trials Despite Patient Death and Pending Class Action Lawsuit 10/22/2015 6:35:48 AM
After Patient Death in Zafgen (ZFGN)'s Phase III Obesity Study, FDA Places Partial Hold on Trial 10/16/2015 6:10:33 AM
Zafgen (ZFGN) Issues Statement 10/15/2015 7:25:41 AM
Breaking News: Zafgen (ZFGN) Breaks Silence About Death in Phase III Obesity Clinical Trial 10/14/2015 7:09:57 AM
Zafgen (ZFGN) Granted Orphan Drug Designation In The European Union For Beloranib, A First-In-Class Metap2 Inhibitor For The Treatment Of Craniopharyngioma 9/30/2015 7:17:26 AM
Zafgen (ZFGN) Announces Transition Of Board Of Directors 9/28/2015 10:52:12 AM
Zafgen (ZFGN) To Present At The Leerink Rare Disease Roundtable 9/25/2015 8:19:40 AM
Zafgen (ZFGN) To Present At Morgan Stanley (MST) Global Healthcare Conference 9/10/2015 10:57:30 AM
Zafgen (ZFGN) Completes Enrollment Of Phase IIb Trial Of Beloranib In Severe Obesity Complicated By Type 2 Diabetes 9/9/2015 7:17:21 AM